# PeptideScanner evidence objects: Palopegteriparatide

Every published version of the records placed with Palopegteriparatide, one section per evidence object. The section anchor is the object's path id; the JSON twin is https://peptidescanner.com/evidence/v1/peptides/palopegteriparatide.json. Selected public evidence only; not medical advice.

- Objects: 16
- Manifest: https://peptidescanner.com/evidence/v1/manifest.json

---

<a id="clinicaltrials-gov-nct07081997-palopegteriparatide-v1"></a>

## ClinicalTrials.gov record NCT07081997

> PeptideScanner retained ClinicalTrials.gov record NCT07081997 at 2026-11-15T21:57:58.320Z. Its registry update date was 2026-11-05, and PeptideScanner's reviewed identity mapping was palopegteriparatide.

- Evidence object: `story:clinicaltrials-gov-nct07081997-palopegteriparatide:v1`
- Evidence domain: Clinical trials
- Date in source: 2026-11-05
- Source checked: 2026-11-15
- Published by PeptideScanner: 2026-11-15
- Story landing page: https://peptidescanner.com/stories/clinicaltrials-gov-nct07081997-palopegteriparatide/
- JSON record: https://peptidescanner.com/evidence/v1/peptides/palopegteriparatide.json#clinicaltrials-gov-nct07081997-palopegteriparatide-v1
- Content SHA-256: `4732f1ee8ee067dd2f7f45fd22c873d64417cad1c0a1b93f4d5d880dc7ef7cd0`

### Claims and source pins

#### Headline

ClinicalTrials.gov record NCT07081997 ([`ctg-observation-nct07081997-2026-11-05-2ba7db736461`](#source-ctg-observation-nct07081997-2026-11-05-2ba7db736461))

#### Summary

PeptideScanner retained ClinicalTrials.gov record NCT07081997 at 2026-11-15T21:57:58.320Z. Its registry update date was 2026-11-05, and PeptideScanner's reviewed identity mapping was palopegteriparatide. ([`ctg-observation-nct07081997-2026-11-05-2ba7db736461`](#source-ctg-observation-nct07081997-2026-11-05-2ba7db736461))

#### Paragraph 1

PeptideScanner retained ClinicalTrials.gov record NCT07081997 at 2026-11-15T21:57:58.320Z. Its registry update date was 2026-11-05, and PeptideScanner's reviewed identity mapping was palopegteriparatide. ([`ctg-observation-nct07081997-2026-11-05-2ba7db736461`](#source-ctg-observation-nct07081997-2026-11-05-2ba7db736461))

#### Paragraph 2

This page reports a dated retained registry observation and does not assert the record's current status; registration is not evidence that an intervention is safe or effective. ([`ctg-observation-nct07081997-2026-11-05-2ba7db736461`](#source-ctg-observation-nct07081997-2026-11-05-2ba7db736461))

### Sources

<a id="source-ctg-observation-nct07081997-2026-11-05-2ba7db736461"></a>
- **ClinicalTrials.gov record NCT07081997 · retained source version 2026-11-05:2ba7db736461e629a7ae31ec9c4fc26392a8c35d8226d122e74cde3091ca5845** — ClinicalTrials.gov; class A. [Open source](https://clinicaltrials.gov/study/NCT07081997) (`ctg-observation-nct07081997-2026-11-05-2ba7db736461`)

### Correction lineage

No correction is recorded for this version.

### Reporting boundaries and unknowns

PeptideScanner reports the cited trial-registry entry and its status at observation. Registration or completion does not establish safety, effectiveness, or regulatory approval.

- Sources outside the selected public PeptideScanner bundle may exist and are not represented by this object.
- This object does not determine whether cited records agree, corroborate one another, or establish scientific truth.
- This object does not determine safety, efficacy, causality, or suitability for any person.

Methodology: https://peptidescanner.com/methodology/
Medical disclaimer: https://peptidescanner.com/medical-disclaimer/

### Suggested citation

PeptideScanner. "ClinicalTrials.gov record NCT07081997." Version 1, published 2026-11-15. https://peptidescanner.com/evidence/v1/peptides/palopegteriparatide.json#clinicaltrials-gov-nct07081997-palopegteriparatide-v1 SHA-256: 4732f1ee8ee067dd2f7f45fd22c873d64417cad1c0a1b93f4d5d880dc7ef7cd0.

---

<a id="clinicaltrials-gov-nct07264634-palopegteriparatide-v1"></a>

## ClinicalTrials.gov record NCT07264634

> PeptideScanner retained ClinicalTrials.gov record NCT07264634 at 2026-11-15T21:57:58.320Z. Its registry update date was 2026-08-07, and PeptideScanner's reviewed identity mapping was palopegteriparatide.

- Evidence object: `story:clinicaltrials-gov-nct07264634-palopegteriparatide:v1`
- Evidence domain: Clinical trials
- Date in source: 2026-08-07
- Source checked: 2026-11-15
- Published by PeptideScanner: 2026-11-15
- Story landing page: https://peptidescanner.com/stories/clinicaltrials-gov-nct07264634-palopegteriparatide/
- JSON record: https://peptidescanner.com/evidence/v1/peptides/palopegteriparatide.json#clinicaltrials-gov-nct07264634-palopegteriparatide-v1
- Content SHA-256: `c0a7e64b22ea79cb4d16c76411886427619cad361a2394b05549ddaa9c1e0326`

### Claims and source pins

#### Headline

ClinicalTrials.gov record NCT07264634 ([`ctg-observation-nct07264634-2026-08-07-2446e4726467`](#source-ctg-observation-nct07264634-2026-08-07-2446e4726467))

#### Summary

PeptideScanner retained ClinicalTrials.gov record NCT07264634 at 2026-11-15T21:57:58.320Z. Its registry update date was 2026-08-07, and PeptideScanner's reviewed identity mapping was palopegteriparatide. ([`ctg-observation-nct07264634-2026-08-07-2446e4726467`](#source-ctg-observation-nct07264634-2026-08-07-2446e4726467))

#### Paragraph 1

PeptideScanner retained ClinicalTrials.gov record NCT07264634 at 2026-11-15T21:57:58.320Z. Its registry update date was 2026-08-07, and PeptideScanner's reviewed identity mapping was palopegteriparatide. ([`ctg-observation-nct07264634-2026-08-07-2446e4726467`](#source-ctg-observation-nct07264634-2026-08-07-2446e4726467))

#### Paragraph 2

This page reports a dated retained registry observation and does not assert the record's current status; registration is not evidence that an intervention is safe or effective. ([`ctg-observation-nct07264634-2026-08-07-2446e4726467`](#source-ctg-observation-nct07264634-2026-08-07-2446e4726467))

### Sources

<a id="source-ctg-observation-nct07264634-2026-08-07-2446e4726467"></a>
- **ClinicalTrials.gov record NCT07264634 · retained source version 2026-08-07:2446e472646770d45688e1cce3de010ccc0e11b65d4a36235053eeeac15101b0** — ClinicalTrials.gov; class A. [Open source](https://clinicaltrials.gov/study/NCT07264634) (`ctg-observation-nct07264634-2026-08-07-2446e4726467`)

### Correction lineage

No correction is recorded for this version.

### Reporting boundaries and unknowns

PeptideScanner reports the cited trial-registry entry and its status at observation. Registration or completion does not establish safety, effectiveness, or regulatory approval.

- Sources outside the selected public PeptideScanner bundle may exist and are not represented by this object.
- This object does not determine whether cited records agree, corroborate one another, or establish scientific truth.
- This object does not determine safety, efficacy, causality, or suitability for any person.

Methodology: https://peptidescanner.com/methodology/
Medical disclaimer: https://peptidescanner.com/medical-disclaimer/

### Suggested citation

PeptideScanner. "ClinicalTrials.gov record NCT07264634." Version 1, published 2026-11-15. https://peptidescanner.com/evidence/v1/peptides/palopegteriparatide.json#clinicaltrials-gov-nct07264634-palopegteriparatide-v1 SHA-256: c0a7e64b22ea79cb4d16c76411886427619cad361a2394b05549ddaa9c1e0326.

---

<a id="clinicaltrials-gov-nct07345494-palopegteriparatide-v1"></a>

## ClinicalTrials.gov record NCT07345494

> PeptideScanner retained ClinicalTrials.gov record NCT07345494 at 2026-11-15T21:57:58.320Z. Its registry update date was 2026-03-02, and PeptideScanner's reviewed identity mapping was palopegteriparatide.

- Evidence object: `story:clinicaltrials-gov-nct07345494-palopegteriparatide:v1`
- Evidence domain: Clinical trials
- Date in source: 2026-03-02
- Source checked: 2026-11-15
- Published by PeptideScanner: 2026-11-15
- Story landing page: https://peptidescanner.com/stories/clinicaltrials-gov-nct07345494-palopegteriparatide/
- JSON record: https://peptidescanner.com/evidence/v1/peptides/palopegteriparatide.json#clinicaltrials-gov-nct07345494-palopegteriparatide-v1
- Content SHA-256: `0f42abd6508a19dea870bb6c6af23611a1ab98e259b8268a419abdfe3c0e9ff4`

### Claims and source pins

#### Headline

ClinicalTrials.gov record NCT07345494 ([`ctg-observation-nct07345494-2026-03-02-8520b4e7ed0c`](#source-ctg-observation-nct07345494-2026-03-02-8520b4e7ed0c))

#### Summary

PeptideScanner retained ClinicalTrials.gov record NCT07345494 at 2026-11-15T21:57:58.320Z. Its registry update date was 2026-03-02, and PeptideScanner's reviewed identity mapping was palopegteriparatide. ([`ctg-observation-nct07345494-2026-03-02-8520b4e7ed0c`](#source-ctg-observation-nct07345494-2026-03-02-8520b4e7ed0c))

#### Paragraph 1

PeptideScanner retained ClinicalTrials.gov record NCT07345494 at 2026-11-15T21:57:58.320Z. Its registry update date was 2026-03-02, and PeptideScanner's reviewed identity mapping was palopegteriparatide. ([`ctg-observation-nct07345494-2026-03-02-8520b4e7ed0c`](#source-ctg-observation-nct07345494-2026-03-02-8520b4e7ed0c))

#### Paragraph 2

This page reports a dated retained registry observation and does not assert the record's current status; registration is not evidence that an intervention is safe or effective. ([`ctg-observation-nct07345494-2026-03-02-8520b4e7ed0c`](#source-ctg-observation-nct07345494-2026-03-02-8520b4e7ed0c))

### Sources

<a id="source-ctg-observation-nct07345494-2026-03-02-8520b4e7ed0c"></a>
- **ClinicalTrials.gov record NCT07345494 · retained source version 2026-03-02:8520b4e7ed0c2865566e16c65659e1e1e2724f05c019088896352d28270176f8** — ClinicalTrials.gov; class A. [Open source](https://clinicaltrials.gov/study/NCT07345494) (`ctg-observation-nct07345494-2026-03-02-8520b4e7ed0c`)

### Correction lineage

No correction is recorded for this version.

### Reporting boundaries and unknowns

PeptideScanner reports the cited trial-registry entry and its status at observation. Registration or completion does not establish safety, effectiveness, or regulatory approval.

- Sources outside the selected public PeptideScanner bundle may exist and are not represented by this object.
- This object does not determine whether cited records agree, corroborate one another, or establish scientific truth.
- This object does not determine safety, efficacy, causality, or suitability for any person.

Methodology: https://peptidescanner.com/methodology/
Medical disclaimer: https://peptidescanner.com/medical-disclaimer/

### Suggested citation

PeptideScanner. "ClinicalTrials.gov record NCT07345494." Version 1, published 2026-11-15. https://peptidescanner.com/evidence/v1/peptides/palopegteriparatide.json#clinicaltrials-gov-nct07345494-palopegteriparatide-v1 SHA-256: 0f42abd6508a19dea870bb6c6af23611a1ab98e259b8268a419abdfe3c0e9ff4.

---

<a id="clinicaltrials-gov-nct07706764-palopegteriparatide-v1"></a>

## ClinicalTrials.gov record NCT07706764

> PeptideScanner retained ClinicalTrials.gov record NCT07706764 at 2026-11-15T21:57:58.320Z. Its registry update date was 2026-07-28, and PeptideScanner's reviewed identity mapping was palopegteriparatide.

- Evidence object: `story:clinicaltrials-gov-nct07706764-palopegteriparatide:v1`
- Evidence domain: Clinical trials
- Date in source: 2026-07-28
- Source checked: 2026-11-15
- Published by PeptideScanner: 2026-11-15
- Story landing page: https://peptidescanner.com/stories/clinicaltrials-gov-nct07706764-palopegteriparatide/
- JSON record: https://peptidescanner.com/evidence/v1/peptides/palopegteriparatide.json#clinicaltrials-gov-nct07706764-palopegteriparatide-v1
- Content SHA-256: `ba5bcab3eb0e8b06f9cf903c2f3cff24eaff95271bf65fbca9844fd73013a26b`

### Claims and source pins

#### Headline

ClinicalTrials.gov record NCT07706764 ([`ctg-observation-nct07706764-2026-07-28-a7c078feb6b9`](#source-ctg-observation-nct07706764-2026-07-28-a7c078feb6b9))

#### Summary

PeptideScanner retained ClinicalTrials.gov record NCT07706764 at 2026-11-15T21:57:58.320Z. Its registry update date was 2026-07-28, and PeptideScanner's reviewed identity mapping was palopegteriparatide. ([`ctg-observation-nct07706764-2026-07-28-a7c078feb6b9`](#source-ctg-observation-nct07706764-2026-07-28-a7c078feb6b9))

#### Paragraph 1

PeptideScanner retained ClinicalTrials.gov record NCT07706764 at 2026-11-15T21:57:58.320Z. Its registry update date was 2026-07-28, and PeptideScanner's reviewed identity mapping was palopegteriparatide. ([`ctg-observation-nct07706764-2026-07-28-a7c078feb6b9`](#source-ctg-observation-nct07706764-2026-07-28-a7c078feb6b9))

#### Paragraph 2

This page reports a dated retained registry observation and does not assert the record's current status; registration is not evidence that an intervention is safe or effective. ([`ctg-observation-nct07706764-2026-07-28-a7c078feb6b9`](#source-ctg-observation-nct07706764-2026-07-28-a7c078feb6b9))

### Sources

<a id="source-ctg-observation-nct07706764-2026-07-28-a7c078feb6b9"></a>
- **ClinicalTrials.gov record NCT07706764 · retained source version 2026-07-28:a7c078feb6b94fcd6896989d776dd26717c57ede614d4bfc0fc5b46d2607cd23** — ClinicalTrials.gov; class A. [Open source](https://clinicaltrials.gov/study/NCT07706764) (`ctg-observation-nct07706764-2026-07-28-a7c078feb6b9`)

### Correction lineage

No correction is recorded for this version.

### Reporting boundaries and unknowns

PeptideScanner reports the cited trial-registry entry and its status at observation. Registration or completion does not establish safety, effectiveness, or regulatory approval.

- Sources outside the selected public PeptideScanner bundle may exist and are not represented by this object.
- This object does not determine whether cited records agree, corroborate one another, or establish scientific truth.
- This object does not determine safety, efficacy, causality, or suitability for any person.

Methodology: https://peptidescanner.com/methodology/
Medical disclaimer: https://peptidescanner.com/medical-disclaimer/

### Suggested citation

PeptideScanner. "ClinicalTrials.gov record NCT07706764." Version 1, published 2026-11-15. https://peptidescanner.com/evidence/v1/peptides/palopegteriparatide.json#clinicaltrials-gov-nct07706764-palopegteriparatide-v1 SHA-256: ba5bcab3eb0e8b06f9cf903c2f3cff24eaff95271bf65fbca9844fd73013a26b.

---

<a id="fda-drugs-nda216490-v1"></a>

## Drugs@FDA application NDA216490

> The official Drugs@FDA dataset lists original submission 1 for NDA 216490 with status AP dated 2024-08-09, and names palopegteriparatide among the application record's active ingredients.

- Evidence object: `story:fda-drugs-nda216490:v1`
- Evidence domain: Regulatory
- Date in source: 2024-08-09
- Source checked: 2026-11-15
- Published by PeptideScanner: 2026-11-15
- Story landing page: https://peptidescanner.com/stories/fda-drugs-nda216490/
- JSON record: https://peptidescanner.com/evidence/v1/peptides/palopegteriparatide.json#fda-drugs-nda216490-v1
- Content SHA-256: `a5926be8e401d5e2a0c877317faa71457fc7ba78f8d36f320dad34ff3cdfea14`

### Claims and source pins

#### Headline

Drugs@FDA application NDA216490 ([`fda-drugs-nda216490-2024-08-09-dad2881ef47a`](#source-fda-drugs-nda216490-2024-08-09-dad2881ef47a))

#### Summary

The official Drugs@FDA dataset lists original submission 1 for NDA 216490 with status AP dated 2024-08-09, and names palopegteriparatide among the application record's active ingredients. ([`fda-drugs-nda216490-2024-08-09-dad2881ef47a`](#source-fda-drugs-nda216490-2024-08-09-dad2881ef47a))

#### Paragraph 1

The official Drugs@FDA dataset lists original submission 1 for NDA 216490 with status AP dated 2024-08-09, and names palopegteriparatide among the application record's active ingredients. ([`fda-drugs-nda216490-2024-08-09-dad2881ef47a`](#source-fda-drugs-nda216490-2024-08-09-dad2881ef47a))

#### Paragraph 2

This page reports bounded application metadata attributed to Drugs@FDA. It does not reproduce labeling, describe an indication, compare products, or provide medical guidance. ([`fda-drugs-nda216490-2024-08-09-dad2881ef47a`](#source-fda-drugs-nda216490-2024-08-09-dad2881ef47a))

### Sources

<a id="source-fda-drugs-nda216490-2024-08-09-dad2881ef47a"></a>
- **Drugs@FDA application NDA216490 · original submission status AP · 2024-08-09 · dataset 2026-11-13** — Drugs@FDA via openFDA; class A. [Open source](https://api.fda.gov/drug/drugsfda.json?search=application_number%3A%22NDA216490%22&limit=1) (`fda-drugs-nda216490-2024-08-09-dad2881ef47a`)

### Correction lineage

No correction is recorded for this version.

### Reporting boundaries and unknowns

PeptideScanner reports the cited regulator or label record. It does not extend that record into broader safety, effectiveness, or approval claims.

- Sources outside the selected public PeptideScanner bundle may exist and are not represented by this object.
- This object does not determine whether cited records agree, corroborate one another, or establish scientific truth.
- This object does not determine safety, efficacy, causality, or suitability for any person.

Methodology: https://peptidescanner.com/methodology/
Medical disclaimer: https://peptidescanner.com/medical-disclaimer/

### Suggested citation

PeptideScanner. "Drugs@FDA application NDA216490." Version 1, published 2026-11-15. https://peptidescanner.com/evidence/v1/peptides/palopegteriparatide.json#fda-drugs-nda216490-v1 SHA-256: a5926be8e401d5e2a0c877317faa71457fc7ba78f8d36f320dad34ff3cdfea14.

---

<a id="federal-register-2025-16269-v1"></a>

## Federal Register notice 2025-16269

> The Federal Register published notice 2025-16269, attributed to FDA and its parent HHS department, on 2025-08-26. Its official title is “Determination of Regulatory Review Period for Purposes of Patent Extension; YORVIPATH,” and PeptideScanner's exact reviewed identity mapping connects the document to Palopegteriparatide.

- Evidence object: `story:federal-register-2025-16269:v1`
- Evidence domain: Regulatory
- Date in source: 2025-08-26
- Source checked: 2026-11-15
- Published by PeptideScanner: 2026-11-15
- Story landing page: https://peptidescanner.com/stories/federal-register-2025-16269/
- JSON record: https://peptidescanner.com/evidence/v1/peptides/palopegteriparatide.json#federal-register-2025-16269-v1
- Content SHA-256: `fa3b88fe22bb816841a935e8c80c5464338459ebd4f1be649ebdcc203a9911dd`

### Claims and source pins

#### Headline

Federal Register notice 2025-16269 ([`federal-register-2025-16269-81ed3b47d7b0`](#source-federal-register-2025-16269-81ed3b47d7b0))

#### Summary

The Federal Register published notice 2025-16269, attributed to FDA and its parent HHS department, on 2025-08-26. Its official title is “Determination of Regulatory Review Period for Purposes of Patent Extension; YORVIPATH,” and PeptideScanner's exact reviewed identity mapping connects the document to Palopegteriparatide. ([`federal-register-2025-16269-81ed3b47d7b0`](#source-federal-register-2025-16269-81ed3b47d7b0))

#### Paragraph 1

The Federal Register published notice 2025-16269, attributed to FDA and its parent HHS department, on 2025-08-26. Its official title is “Determination of Regulatory Review Period for Purposes of Patent Extension; YORVIPATH,” and PeptideScanner's exact reviewed identity mapping connects the document to Palopegteriparatide. ([`federal-register-2025-16269-81ed3b47d7b0`](#source-federal-register-2025-16269-81ed3b47d7b0))

#### Paragraph 2

This page reports bounded metadata from a Federal Register document attributed to FDA and its parent HHS department, and links to the official GovInfo PDF. It does not interpret legal effect, approval, safety, effectiveness, compounding status, or medical use. ([`federal-register-2025-16269-81ed3b47d7b0`](#source-federal-register-2025-16269-81ed3b47d7b0))

### Sources

<a id="source-federal-register-2025-16269-81ed3b47d7b0"></a>
- **Federal Register notice 2025-16269 · published 2025-08-26 · Determination of Regulatory Review Period for Purposes of Patent Extension; YORVIPATH** — Federal Register via GovInfo; class A. [Open source](https://www.govinfo.gov/content/pkg/FR-2025-08-26/pdf/2025-16269.pdf) (`federal-register-2025-16269-81ed3b47d7b0`)

### Correction lineage

No correction is recorded for this version.

### Reporting boundaries and unknowns

PeptideScanner reports the cited regulator or label record. It does not extend that record into broader safety, effectiveness, or approval claims.

- Sources outside the selected public PeptideScanner bundle may exist and are not represented by this object.
- This object does not determine whether cited records agree, corroborate one another, or establish scientific truth.
- This object does not determine safety, efficacy, causality, or suitability for any person.

Methodology: https://peptidescanner.com/methodology/
Medical disclaimer: https://peptidescanner.com/medical-disclaimer/

### Suggested citation

PeptideScanner. "Federal Register notice 2025-16269." Version 1, published 2026-11-15. https://peptidescanner.com/evidence/v1/peptides/palopegteriparatide.json#federal-register-2025-16269-v1 SHA-256: fa3b88fe22bb816841a935e8c80c5464338459ebd4f1be649ebdcc203a9911dd.

---

<a id="federal-register-2026-10277-v1"></a>

## Federal Register notice 2026-10277

> The Federal Register published notice 2026-10277, attributed to FDA and its parent HHS department, on 2026-05-22. Its official title is “Product-Specific Guidances; Draft and Revised Draft Guidances for Industry; Availability,” and PeptideScanner's exact reviewed identity mapping connects the document to Palopegteriparatide.

- Evidence object: `story:federal-register-2026-10277:v1`
- Evidence domain: Regulatory
- Date in source: 2026-05-22
- Source checked: 2026-11-15
- Published by PeptideScanner: 2026-11-15
- Story landing page: https://peptidescanner.com/stories/federal-register-2026-10277/
- JSON record: https://peptidescanner.com/evidence/v1/peptides/palopegteriparatide.json#federal-register-2026-10277-v1
- Content SHA-256: `90028d6c73acec07c92ba1c33c520ce4846e40f5ab4a704f6c27e36fbd6b7ac1`

### Claims and source pins

#### Headline

Federal Register notice 2026-10277 ([`federal-register-2026-10277-dec1a634fb73`](#source-federal-register-2026-10277-dec1a634fb73))

#### Summary

The Federal Register published notice 2026-10277, attributed to FDA and its parent HHS department, on 2026-05-22. Its official title is “Product-Specific Guidances; Draft and Revised Draft Guidances for Industry; Availability,” and PeptideScanner's exact reviewed identity mapping connects the document to Palopegteriparatide. ([`federal-register-2026-10277-dec1a634fb73`](#source-federal-register-2026-10277-dec1a634fb73))

#### Paragraph 1

The Federal Register published notice 2026-10277, attributed to FDA and its parent HHS department, on 2026-05-22. Its official title is “Product-Specific Guidances; Draft and Revised Draft Guidances for Industry; Availability,” and PeptideScanner's exact reviewed identity mapping connects the document to Palopegteriparatide. ([`federal-register-2026-10277-dec1a634fb73`](#source-federal-register-2026-10277-dec1a634fb73))

#### Paragraph 2

This page reports bounded metadata from a Federal Register document attributed to FDA and its parent HHS department, and links to the official GovInfo PDF. It does not interpret legal effect, approval, safety, effectiveness, compounding status, or medical use. ([`federal-register-2026-10277-dec1a634fb73`](#source-federal-register-2026-10277-dec1a634fb73))

### Sources

<a id="source-federal-register-2026-10277-dec1a634fb73"></a>
- **Federal Register notice 2026-10277 · published 2026-05-22 · Product-Specific Guidances; Draft and Revised Draft Guidances for Industry; Availability** — Federal Register via GovInfo; class A. [Open source](https://www.govinfo.gov/content/pkg/FR-2026-05-22/pdf/2026-10277.pdf) (`federal-register-2026-10277-dec1a634fb73`)

### Correction lineage

No correction is recorded for this version.

### Reporting boundaries and unknowns

PeptideScanner reports the cited regulator or label record. It does not extend that record into broader safety, effectiveness, or approval claims.

- Sources outside the selected public PeptideScanner bundle may exist and are not represented by this object.
- This object does not determine whether cited records agree, corroborate one another, or establish scientific truth.
- This object does not determine safety, efficacy, causality, or suitability for any person.

Methodology: https://peptidescanner.com/methodology/
Medical disclaimer: https://peptidescanner.com/medical-disclaimer/

### Suggested citation

PeptideScanner. "Federal Register notice 2026-10277." Version 1, published 2026-11-15. https://peptidescanner.com/evidence/v1/peptides/palopegteriparatide.json#federal-register-2026-10277-v1 SHA-256: 90028d6c73acec07c92ba1c33c520ce4846e40f5ab4a704f6c27e36fbd6b7ac1.

---

<a id="pubmed-pmid-39437769-palopegteriparatide-v1"></a>

## Palopegteriparatide.

> PubMed lists PMID 39437769 in American journal of health-system pharmacy : AJHP : official journal of the American Society of Health-System Pharmacists as Journal Article, with publication-date metadata of 2025-01-06 (day precision). PeptideScanner associated the retained record with the identity slug palopegteriparatide. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.

- Evidence object: `story:pubmed-pmid-39437769-palopegteriparatide:v1`
- Evidence domain: Literature metadata
- Date in source: 2025-01-06
- Source checked: 2026-11-15
- Published by PeptideScanner: 2026-11-15
- Story landing page: https://peptidescanner.com/stories/pubmed-pmid-39437769-palopegteriparatide/
- JSON record: https://peptidescanner.com/evidence/v1/peptides/palopegteriparatide.json#pubmed-pmid-39437769-palopegteriparatide-v1
- Content SHA-256: `bbea7de7f4ebdb296913a9d4dce1ead9c897913c890b2645358da4933ef2b370`

### Claims and source pins

#### Headline

Palopegteriparatide. ([`pubmed-observation-pmid-39437769-2025-01-06-00b610d803a4`](#source-pubmed-observation-pmid-39437769-2025-01-06-00b610d803a4))

#### Summary

PubMed lists PMID 39437769 in American journal of health-system pharmacy : AJHP : official journal of the American Society of Health-System Pharmacists as Journal Article, with publication-date metadata of 2025-01-06 (day precision). PeptideScanner associated the retained record with the identity slug palopegteriparatide. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings. ([`pubmed-observation-pmid-39437769-2025-01-06-00b610d803a4`](#source-pubmed-observation-pmid-39437769-2025-01-06-00b610d803a4))

#### Paragraph 1

PubMed lists PMID 39437769 in American journal of health-system pharmacy : AJHP : official journal of the American Society of Health-System Pharmacists as Journal Article, with publication-date metadata of 2025-01-06 (day precision). PeptideScanner associated the retained record with the identity slug palopegteriparatide. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings. ([`pubmed-observation-pmid-39437769-2025-01-06-00b610d803a4`](#source-pubmed-observation-pmid-39437769-2025-01-06-00b610d803a4))

#### Paragraph 2

This page reproduces bounded bibliographic metadata attributed to PubMed. Its title and publication details are source metadata, not PeptideScanner's endorsement or an assertion of safety, efficacy, or scientific truth. ([`pubmed-observation-pmid-39437769-2025-01-06-00b610d803a4`](#source-pubmed-observation-pmid-39437769-2025-01-06-00b610d803a4))

### Sources

<a id="source-pubmed-observation-pmid-39437769-2025-01-06-00b610d803a4"></a>
- **Palopegteriparatide. · retained source version 1:2025-01-06:current:00b610d803a4af5099cdd61d87910613bd62ee2b2cac8a5c4ce4059ddeade246** — PubMed; class A. [Open source](https://pubmed.ncbi.nlm.nih.gov/39437769/) (`pubmed-observation-pmid-39437769-2025-01-06-00b610d803a4`)

### Correction lineage

No correction is recorded for this version.

### Reporting boundaries and unknowns

PeptideScanner reproduces bounded bibliographic metadata attributed to PubMed. It does not summarize or endorse the article's findings.

- Sources outside the selected public PeptideScanner bundle may exist and are not represented by this object.
- This object does not determine whether cited records agree, corroborate one another, or establish scientific truth.
- This object does not determine safety, efficacy, causality, or suitability for any person.

Methodology: https://peptidescanner.com/methodology/
Medical disclaimer: https://peptidescanner.com/medical-disclaimer/

### Suggested citation

PeptideScanner. "Palopegteriparatide." Version 1, published 2026-11-15. https://peptidescanner.com/evidence/v1/peptides/palopegteriparatide.json#pubmed-pmid-39437769-palopegteriparatide-v1 SHA-256: bbea7de7f4ebdb296913a9d4dce1ead9c897913c890b2645358da4933ef2b370.

---

<a id="pubmed-pmid-41134515-palopegteriparatide-v1"></a>

## Value Contribution of Palopegteriparatide in Adult Patients with Chronic Hypoparathyroidism using Multicriteria Decision Analysis (MCDA).

> PubMed lists PMID 41134515 in Advances in therapy as Journal Article, with publication-date metadata of 2025-10-24 (day precision). PeptideScanner associated the retained record with the identity slug palopegteriparatide. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.

- Evidence object: `story:pubmed-pmid-41134515-palopegteriparatide:v1`
- Evidence domain: Literature metadata
- Date in source: 2025-11-17
- Source checked: 2026-11-15
- Published by PeptideScanner: 2026-11-15
- Story landing page: https://peptidescanner.com/stories/pubmed-pmid-41134515-palopegteriparatide/
- JSON record: https://peptidescanner.com/evidence/v1/peptides/palopegteriparatide.json#pubmed-pmid-41134515-palopegteriparatide-v1
- Content SHA-256: `86e19a0844999118a1b38441cdc279cea784bdeee5e6d57889149ab77a10757f`

### Claims and source pins

#### Headline

Value Contribution of Palopegteriparatide in Adult Patients with Chronic Hypoparathyroidism using Multicriteria Decision Analysis (MCDA). ([`pubmed-observation-pmid-41134515-2025-11-17-4e33113f71d6`](#source-pubmed-observation-pmid-41134515-2025-11-17-4e33113f71d6))

#### Summary

PubMed lists PMID 41134515 in Advances in therapy as Journal Article, with publication-date metadata of 2025-10-24 (day precision). PeptideScanner associated the retained record with the identity slug palopegteriparatide. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings. ([`pubmed-observation-pmid-41134515-2025-11-17-4e33113f71d6`](#source-pubmed-observation-pmid-41134515-2025-11-17-4e33113f71d6))

#### Paragraph 1

PubMed lists PMID 41134515 in Advances in therapy as Journal Article, with publication-date metadata of 2025-10-24 (day precision). PeptideScanner associated the retained record with the identity slug palopegteriparatide. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings. ([`pubmed-observation-pmid-41134515-2025-11-17-4e33113f71d6`](#source-pubmed-observation-pmid-41134515-2025-11-17-4e33113f71d6))

#### Paragraph 2

This page reproduces bounded bibliographic metadata attributed to PubMed. Its title and publication details are source metadata, not PeptideScanner's endorsement or an assertion of safety, efficacy, or scientific truth. ([`pubmed-observation-pmid-41134515-2025-11-17-4e33113f71d6`](#source-pubmed-observation-pmid-41134515-2025-11-17-4e33113f71d6))

### Sources

<a id="source-pubmed-observation-pmid-41134515-2025-11-17-4e33113f71d6"></a>
- **Value Contribution of Palopegteriparatide in Adult Patients with Chronic Hypoparathyroidism using Multicriteria Decision Analysis (MCDA). · retained source version 1:2025-11-17:current:4e33113f71d6cdb51785bd50c35ca8c6305d5520c0602002d7c831adf2d96c19** — PubMed; class A. [Open source](https://pubmed.ncbi.nlm.nih.gov/41134515/) (`pubmed-observation-pmid-41134515-2025-11-17-4e33113f71d6`)

### Correction lineage

No correction is recorded for this version.

### Reporting boundaries and unknowns

PeptideScanner reproduces bounded bibliographic metadata attributed to PubMed. It does not summarize or endorse the article's findings.

- Sources outside the selected public PeptideScanner bundle may exist and are not represented by this object.
- This object does not determine whether cited records agree, corroborate one another, or establish scientific truth.
- This object does not determine safety, efficacy, causality, or suitability for any person.

Methodology: https://peptidescanner.com/methodology/
Medical disclaimer: https://peptidescanner.com/medical-disclaimer/

### Suggested citation

PeptideScanner. "Value Contribution of Palopegteriparatide in Adult Patients with Chronic Hypoparathyroidism using Multicriteria Decision Analysis (MCDA)." Version 1, published 2026-11-15. https://peptidescanner.com/evidence/v1/peptides/palopegteriparatide.json#pubmed-pmid-41134515-palopegteriparatide-v1 SHA-256: 86e19a0844999118a1b38441cdc279cea784bdeee5e6d57889149ab77a10757f.

---

<a id="pubmed-pmid-41636590-palopegteriparatide-v1"></a>

## Palopegteriparatide for adults with chronic hypoparathyroidism: skeletal dynamics through 3 years of the phase 2 PaTH forward trial.

> PubMed lists PMID 41636590 in Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research as Journal Article, Randomized Controlled Trial, with publication-date metadata of 2026-09-24 (day precision). PeptideScanner associated the retained record with the identity slug palopegteriparatide. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.

- Evidence object: `story:pubmed-pmid-41636590-palopegteriparatide:v1`
- Evidence domain: Literature metadata
- Date in source: 2026-10-01
- Source checked: 2026-11-15
- Published by PeptideScanner: 2026-11-15
- Story landing page: https://peptidescanner.com/stories/pubmed-pmid-41636590-palopegteriparatide/
- JSON record: https://peptidescanner.com/evidence/v1/peptides/palopegteriparatide.json#pubmed-pmid-41636590-palopegteriparatide-v1
- Content SHA-256: `e6add9e18f483f79c504b96e86b1d233931eccf6685ca4d78f4363b255a2907b`

### Claims and source pins

#### Headline

Palopegteriparatide for adults with chronic hypoparathyroidism: skeletal dynamics through 3 years of the phase 2 PaTH forward trial. ([`pubmed-observation-pmid-41636590-2026-10-01-7bfe14d7c30c`](#source-pubmed-observation-pmid-41636590-2026-10-01-7bfe14d7c30c))

#### Summary

PubMed lists PMID 41636590 in Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research as Journal Article, Randomized Controlled Trial, with publication-date metadata of 2026-09-24 (day precision). PeptideScanner associated the retained record with the identity slug palopegteriparatide. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings. ([`pubmed-observation-pmid-41636590-2026-10-01-7bfe14d7c30c`](#source-pubmed-observation-pmid-41636590-2026-10-01-7bfe14d7c30c))

#### Paragraph 1

PubMed lists PMID 41636590 in Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research as Journal Article, Randomized Controlled Trial, with publication-date metadata of 2026-09-24 (day precision). PeptideScanner associated the retained record with the identity slug palopegteriparatide. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings. ([`pubmed-observation-pmid-41636590-2026-10-01-7bfe14d7c30c`](#source-pubmed-observation-pmid-41636590-2026-10-01-7bfe14d7c30c))

#### Paragraph 2

This page reproduces bounded bibliographic metadata attributed to PubMed. Its title and publication details are source metadata, not PeptideScanner's endorsement or an assertion of safety, efficacy, or scientific truth. ([`pubmed-observation-pmid-41636590-2026-10-01-7bfe14d7c30c`](#source-pubmed-observation-pmid-41636590-2026-10-01-7bfe14d7c30c))

### Sources

<a id="source-pubmed-observation-pmid-41636590-2026-10-01-7bfe14d7c30c"></a>
- **Palopegteriparatide for adults with chronic hypoparathyroidism: skeletal dynamics through 3 years of the phase 2 PaTH forward trial. · retained source version 1:2026-10-01:current:7bfe14d7c30c033cf8252740f83c0dad532329f44e56ab64ccf2a64f5b458390** — PubMed; class A. [Open source](https://pubmed.ncbi.nlm.nih.gov/41636590/) (`pubmed-observation-pmid-41636590-2026-10-01-7bfe14d7c30c`)

### Correction lineage

No correction is recorded for this version.

### Reporting boundaries and unknowns

PeptideScanner reproduces bounded bibliographic metadata attributed to PubMed. It does not summarize or endorse the article's findings.

- Sources outside the selected public PeptideScanner bundle may exist and are not represented by this object.
- This object does not determine whether cited records agree, corroborate one another, or establish scientific truth.
- This object does not determine safety, efficacy, causality, or suitability for any person.

Methodology: https://peptidescanner.com/methodology/
Medical disclaimer: https://peptidescanner.com/medical-disclaimer/

### Suggested citation

PeptideScanner. "Palopegteriparatide for adults with chronic hypoparathyroidism: skeletal dynamics through 3 years of the phase 2 PaTH forward trial." Version 1, published 2026-11-15. https://peptidescanner.com/evidence/v1/peptides/palopegteriparatide.json#pubmed-pmid-41636590-palopegteriparatide-v1 SHA-256: e6add9e18f483f79c504b96e86b1d233931eccf6685ca4d78f4363b255a2907b.

---

<a id="pubmed-pmid-42139093-palopegteriparatide-v1"></a>

## Palopegteriparatide therapy for hypoparathyroidism: targeting the PTH receptor rouses the sleeping skeleton.

> PubMed lists PMID 42139093 in Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research as Journal Article, with publication-date metadata of 2026-09-24 (day precision). PeptideScanner associated the retained record with the identity slug palopegteriparatide. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.

- Evidence object: `story:pubmed-pmid-42139093-palopegteriparatide:v1`
- Evidence domain: Literature metadata
- Date in source: 2026-09-27
- Source checked: 2026-11-15
- Published by PeptideScanner: 2026-11-15
- Story landing page: https://peptidescanner.com/stories/pubmed-pmid-42139093-palopegteriparatide/
- JSON record: https://peptidescanner.com/evidence/v1/peptides/palopegteriparatide.json#pubmed-pmid-42139093-palopegteriparatide-v1
- Content SHA-256: `52ba39380532b00bbeef636cb1356b76f2f12fe5f123058d0bbfbfc9e45b4d62`

### Claims and source pins

#### Headline

Palopegteriparatide therapy for hypoparathyroidism: targeting the PTH receptor rouses the sleeping skeleton. ([`pubmed-observation-pmid-42139093-2026-09-27-1de91bfcd244`](#source-pubmed-observation-pmid-42139093-2026-09-27-1de91bfcd244))

#### Summary

PubMed lists PMID 42139093 in Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research as Journal Article, with publication-date metadata of 2026-09-24 (day precision). PeptideScanner associated the retained record with the identity slug palopegteriparatide. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings. ([`pubmed-observation-pmid-42139093-2026-09-27-1de91bfcd244`](#source-pubmed-observation-pmid-42139093-2026-09-27-1de91bfcd244))

#### Paragraph 1

PubMed lists PMID 42139093 in Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research as Journal Article, with publication-date metadata of 2026-09-24 (day precision). PeptideScanner associated the retained record with the identity slug palopegteriparatide. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings. ([`pubmed-observation-pmid-42139093-2026-09-27-1de91bfcd244`](#source-pubmed-observation-pmid-42139093-2026-09-27-1de91bfcd244))

#### Paragraph 2

This page reproduces bounded bibliographic metadata attributed to PubMed. Its title and publication details are source metadata, not PeptideScanner's endorsement or an assertion of safety, efficacy, or scientific truth. ([`pubmed-observation-pmid-42139093-2026-09-27-1de91bfcd244`](#source-pubmed-observation-pmid-42139093-2026-09-27-1de91bfcd244))

### Sources

<a id="source-pubmed-observation-pmid-42139093-2026-09-27-1de91bfcd244"></a>
- **Palopegteriparatide therapy for hypoparathyroidism: targeting the PTH receptor rouses the sleeping skeleton. · retained source version 1:2026-09-27:current:1de91bfcd2448619830e88940a69d9cbbfe0921aa8465096ba3b819042c35cbd** — PubMed; class A. [Open source](https://pubmed.ncbi.nlm.nih.gov/42139093/) (`pubmed-observation-pmid-42139093-2026-09-27-1de91bfcd244`)

### Correction lineage

No correction is recorded for this version.

### Reporting boundaries and unknowns

PeptideScanner reproduces bounded bibliographic metadata attributed to PubMed. It does not summarize or endorse the article's findings.

- Sources outside the selected public PeptideScanner bundle may exist and are not represented by this object.
- This object does not determine whether cited records agree, corroborate one another, or establish scientific truth.
- This object does not determine safety, efficacy, causality, or suitability for any person.

Methodology: https://peptidescanner.com/methodology/
Medical disclaimer: https://peptidescanner.com/medical-disclaimer/

### Suggested citation

PeptideScanner. "Palopegteriparatide therapy for hypoparathyroidism: targeting the PTH receptor rouses the sleeping skeleton." Version 1, published 2026-11-15. https://peptidescanner.com/evidence/v1/peptides/palopegteriparatide.json#pubmed-pmid-42139093-palopegteriparatide-v1 SHA-256: 52ba39380532b00bbeef636cb1356b76f2f12fe5f123058d0bbfbfc9e45b4d62.

---

<a id="pubmed-pmid-42440695-palopegteriparatide-v1"></a>

## Pharmacodynamics of sustained levels of PTH following palopegteriparatide treatment in adults with hypoparathyroidism.

> PubMed lists PMID 42440695 in Journal of the Endocrine Society as Journal Article, with publication-date metadata of 2026-04-18 (day precision). PeptideScanner associated the retained record with the identity slug palopegteriparatide. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.

- Evidence object: `story:pubmed-pmid-42440695-palopegteriparatide:v1`
- Evidence domain: Literature metadata
- Date in source: 2026-08-13
- Source checked: 2026-11-15
- Published by PeptideScanner: 2026-11-15
- Story landing page: https://peptidescanner.com/stories/pubmed-pmid-42440695-palopegteriparatide/
- JSON record: https://peptidescanner.com/evidence/v1/peptides/palopegteriparatide.json#pubmed-pmid-42440695-palopegteriparatide-v1
- Content SHA-256: `e8ca92f24541447ded24ce9bcfc310f727483bf41011186e2d6d7b273db3821c`

### Claims and source pins

#### Headline

Pharmacodynamics of sustained levels of PTH following palopegteriparatide treatment in adults with hypoparathyroidism. ([`pubmed-observation-pmid-42440695-2026-08-13-28ffc0c1ea19`](#source-pubmed-observation-pmid-42440695-2026-08-13-28ffc0c1ea19))

#### Summary

PubMed lists PMID 42440695 in Journal of the Endocrine Society as Journal Article, with publication-date metadata of 2026-04-18 (day precision). PeptideScanner associated the retained record with the identity slug palopegteriparatide. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings. ([`pubmed-observation-pmid-42440695-2026-08-13-28ffc0c1ea19`](#source-pubmed-observation-pmid-42440695-2026-08-13-28ffc0c1ea19))

#### Paragraph 1

PubMed lists PMID 42440695 in Journal of the Endocrine Society as Journal Article, with publication-date metadata of 2026-04-18 (day precision). PeptideScanner associated the retained record with the identity slug palopegteriparatide. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings. ([`pubmed-observation-pmid-42440695-2026-08-13-28ffc0c1ea19`](#source-pubmed-observation-pmid-42440695-2026-08-13-28ffc0c1ea19))

#### Paragraph 2

This page reproduces bounded bibliographic metadata attributed to PubMed. Its title and publication details are source metadata, not PeptideScanner's endorsement or an assertion of safety, efficacy, or scientific truth. ([`pubmed-observation-pmid-42440695-2026-08-13-28ffc0c1ea19`](#source-pubmed-observation-pmid-42440695-2026-08-13-28ffc0c1ea19))

### Sources

<a id="source-pubmed-observation-pmid-42440695-2026-08-13-28ffc0c1ea19"></a>
- **Pharmacodynamics of sustained levels of PTH following palopegteriparatide treatment in adults with hypoparathyroidism. · retained source version 1:2026-08-13:current:28ffc0c1ea19b29afcfde16d1de3da83bdd02fb208f6768360a76e2a8f619e3c** — PubMed; class A. [Open source](https://pubmed.ncbi.nlm.nih.gov/42440695/) (`pubmed-observation-pmid-42440695-2026-08-13-28ffc0c1ea19`)

### Correction lineage

No correction is recorded for this version.

### Reporting boundaries and unknowns

PeptideScanner reproduces bounded bibliographic metadata attributed to PubMed. It does not summarize or endorse the article's findings.

- Sources outside the selected public PeptideScanner bundle may exist and are not represented by this object.
- This object does not determine whether cited records agree, corroborate one another, or establish scientific truth.
- This object does not determine safety, efficacy, causality, or suitability for any person.

Methodology: https://peptidescanner.com/methodology/
Medical disclaimer: https://peptidescanner.com/medical-disclaimer/

### Suggested citation

PeptideScanner. "Pharmacodynamics of sustained levels of PTH following palopegteriparatide treatment in adults with hypoparathyroidism." Version 1, published 2026-11-15. https://peptidescanner.com/evidence/v1/peptides/palopegteriparatide.json#pubmed-pmid-42440695-palopegteriparatide-v1 SHA-256: e8ca92f24541447ded24ce9bcfc310f727483bf41011186e2d6d7b273db3821c.

---

<a id="pubmed-pmid-42614145-palopegteriparatide-v1"></a>

## Palopegteriparatide treatment for hypoparathyroidism in autoimmune polyendocrinopathy-candidiasis-ectodermal dystrophy: a case series and literature update.

> PubMed lists PMID 42614145 in JBMR plus as Case Reports, Journal Article, with publication-date metadata of 2026-07-21 (day precision). PeptideScanner associated the retained record with the identity slug palopegteriparatide. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.

- Evidence object: `story:pubmed-pmid-42614145-palopegteriparatide:v1`
- Evidence domain: Literature metadata
- Date in source: 2026-08-20
- Source checked: 2026-11-15
- Published by PeptideScanner: 2026-11-15
- Story landing page: https://peptidescanner.com/stories/pubmed-pmid-42614145-palopegteriparatide/
- JSON record: https://peptidescanner.com/evidence/v1/peptides/palopegteriparatide.json#pubmed-pmid-42614145-palopegteriparatide-v1
- Content SHA-256: `f670493c0ee0a9aba176cd025d37f880fb3b0f71d33fa774cc355ac3a16df0cf`

### Claims and source pins

#### Headline

Palopegteriparatide treatment for hypoparathyroidism in autoimmune polyendocrinopathy-candidiasis-ectodermal dystrophy: a case series and literature update. ([`pubmed-observation-pmid-42614145-2026-08-20-9de6515f2d50`](#source-pubmed-observation-pmid-42614145-2026-08-20-9de6515f2d50))

#### Summary

PubMed lists PMID 42614145 in JBMR plus as Case Reports, Journal Article, with publication-date metadata of 2026-07-21 (day precision). PeptideScanner associated the retained record with the identity slug palopegteriparatide. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings. ([`pubmed-observation-pmid-42614145-2026-08-20-9de6515f2d50`](#source-pubmed-observation-pmid-42614145-2026-08-20-9de6515f2d50))

#### Paragraph 1

PubMed lists PMID 42614145 in JBMR plus as Case Reports, Journal Article, with publication-date metadata of 2026-07-21 (day precision). PeptideScanner associated the retained record with the identity slug palopegteriparatide. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings. ([`pubmed-observation-pmid-42614145-2026-08-20-9de6515f2d50`](#source-pubmed-observation-pmid-42614145-2026-08-20-9de6515f2d50))

#### Paragraph 2

This page reproduces bounded bibliographic metadata attributed to PubMed. Its title and publication details are source metadata, not PeptideScanner's endorsement or an assertion of safety, efficacy, or scientific truth. ([`pubmed-observation-pmid-42614145-2026-08-20-9de6515f2d50`](#source-pubmed-observation-pmid-42614145-2026-08-20-9de6515f2d50))

### Sources

<a id="source-pubmed-observation-pmid-42614145-2026-08-20-9de6515f2d50"></a>
- **Palopegteriparatide treatment for hypoparathyroidism in autoimmune polyendocrinopathy-candidiasis-ectodermal dystrophy: a case series and literature update. · retained source version 1:2026-08-20:current:9de6515f2d507e0054f5710827fbc51cbae7b7992f069527cd1e8009ca059d3f** — PubMed; class A. [Open source](https://pubmed.ncbi.nlm.nih.gov/42614145/) (`pubmed-observation-pmid-42614145-2026-08-20-9de6515f2d50`)

### Correction lineage

No correction is recorded for this version.

### Reporting boundaries and unknowns

PeptideScanner reproduces bounded bibliographic metadata attributed to PubMed. It does not summarize or endorse the article's findings.

- Sources outside the selected public PeptideScanner bundle may exist and are not represented by this object.
- This object does not determine whether cited records agree, corroborate one another, or establish scientific truth.
- This object does not determine safety, efficacy, causality, or suitability for any person.

Methodology: https://peptidescanner.com/methodology/
Medical disclaimer: https://peptidescanner.com/medical-disclaimer/

### Suggested citation

PeptideScanner. "Palopegteriparatide treatment for hypoparathyroidism in autoimmune polyendocrinopathy-candidiasis-ectodermal dystrophy: a case series and literature update." Version 1, published 2026-11-15. https://peptidescanner.com/evidence/v1/peptides/palopegteriparatide.json#pubmed-pmid-42614145-palopegteriparatide-v1 SHA-256: f670493c0ee0a9aba176cd025d37f880fb3b0f71d33fa774cc355ac3a16df0cf.

---

<a id="pubmed-pmid-42789535-palopegteriparatide-v1"></a>

## Off-label palopegteriparatide for severe pediatric postsurgical hypocalcemia.

> PubMed lists PMID 42789535 in European journal of endocrinology as Journal Article, Case Reports, with publication-date metadata of 2026-10-05 (day precision). PeptideScanner associated the retained record with the identity slug palopegteriparatide. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.

- Evidence object: `story:pubmed-pmid-42789535-palopegteriparatide:v1`
- Evidence domain: Literature metadata
- Date in source: 2026-10-07
- Source checked: 2026-11-15
- Published by PeptideScanner: 2026-11-15
- Story landing page: https://peptidescanner.com/stories/pubmed-pmid-42789535-palopegteriparatide/
- JSON record: https://peptidescanner.com/evidence/v1/peptides/palopegteriparatide.json#pubmed-pmid-42789535-palopegteriparatide-v1
- Content SHA-256: `34c423343ea85275a5f95e7dbd4e3772c44ee1e1b59bae593bf310fc9a6524e3`

### Claims and source pins

#### Headline

Off-label palopegteriparatide for severe pediatric postsurgical hypocalcemia. ([`pubmed-observation-pmid-42789535-2026-10-07-8566f9c150be`](#source-pubmed-observation-pmid-42789535-2026-10-07-8566f9c150be))

#### Summary

PubMed lists PMID 42789535 in European journal of endocrinology as Journal Article, Case Reports, with publication-date metadata of 2026-10-05 (day precision). PeptideScanner associated the retained record with the identity slug palopegteriparatide. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings. ([`pubmed-observation-pmid-42789535-2026-10-07-8566f9c150be`](#source-pubmed-observation-pmid-42789535-2026-10-07-8566f9c150be))

#### Paragraph 1

PubMed lists PMID 42789535 in European journal of endocrinology as Journal Article, Case Reports, with publication-date metadata of 2026-10-05 (day precision). PeptideScanner associated the retained record with the identity slug palopegteriparatide. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings. ([`pubmed-observation-pmid-42789535-2026-10-07-8566f9c150be`](#source-pubmed-observation-pmid-42789535-2026-10-07-8566f9c150be))

#### Paragraph 2

This page reproduces bounded bibliographic metadata attributed to PubMed. Its title and publication details are source metadata, not PeptideScanner's endorsement or an assertion of safety, efficacy, or scientific truth. ([`pubmed-observation-pmid-42789535-2026-10-07-8566f9c150be`](#source-pubmed-observation-pmid-42789535-2026-10-07-8566f9c150be))

### Sources

<a id="source-pubmed-observation-pmid-42789535-2026-10-07-8566f9c150be"></a>
- **Off-label palopegteriparatide for severe pediatric postsurgical hypocalcemia. · retained source version 1:2026-10-07:current:8566f9c150bed53310c87f7b27359ca29467d8e4c4c718afbddd0984cd8d27f6** — PubMed; class A. [Open source](https://pubmed.ncbi.nlm.nih.gov/42789535/) (`pubmed-observation-pmid-42789535-2026-10-07-8566f9c150be`)

### Correction lineage

No correction is recorded for this version.

### Reporting boundaries and unknowns

PeptideScanner reproduces bounded bibliographic metadata attributed to PubMed. It does not summarize or endorse the article's findings.

- Sources outside the selected public PeptideScanner bundle may exist and are not represented by this object.
- This object does not determine whether cited records agree, corroborate one another, or establish scientific truth.
- This object does not determine safety, efficacy, causality, or suitability for any person.

Methodology: https://peptidescanner.com/methodology/
Medical disclaimer: https://peptidescanner.com/medical-disclaimer/

### Suggested citation

PeptideScanner. "Off-label palopegteriparatide for severe pediatric postsurgical hypocalcemia." Version 1, published 2026-11-15. https://peptidescanner.com/evidence/v1/peptides/palopegteriparatide.json#pubmed-pmid-42789535-palopegteriparatide-v1 SHA-256: 34c423343ea85275a5f95e7dbd4e3772c44ee1e1b59bae593bf310fc9a6524e3.

---

<a id="pubmed-pmid-42871663-palopegteriparatide-v1"></a>

## Discontinuation of palopegteriparatide in chronic hypoparathyroidism without rebound hypocalcemia.

> PubMed lists PMID 42871663 in JCEM case reports as Case Reports, Journal Article, with publication-date metadata of 2026-10-13 (day precision). PeptideScanner associated the retained record with the identity slug palopegteriparatide. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.

- Evidence object: `story:pubmed-pmid-42871663-palopegteriparatide:v1`
- Evidence domain: Literature metadata
- Date in source: 2026-10-15
- Source checked: 2026-11-15
- Published by PeptideScanner: 2026-11-15
- Story landing page: https://peptidescanner.com/stories/pubmed-pmid-42871663-palopegteriparatide/
- JSON record: https://peptidescanner.com/evidence/v1/peptides/palopegteriparatide.json#pubmed-pmid-42871663-palopegteriparatide-v1
- Content SHA-256: `669081e916a66e8c4aa5cece983ad88232aa9e9c2bb2eac82752ff96bda328ef`

### Claims and source pins

#### Headline

Discontinuation of palopegteriparatide in chronic hypoparathyroidism without rebound hypocalcemia. ([`pubmed-observation-pmid-42871663-2026-10-15-72edcd9bc290`](#source-pubmed-observation-pmid-42871663-2026-10-15-72edcd9bc290))

#### Summary

PubMed lists PMID 42871663 in JCEM case reports as Case Reports, Journal Article, with publication-date metadata of 2026-10-13 (day precision). PeptideScanner associated the retained record with the identity slug palopegteriparatide. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings. ([`pubmed-observation-pmid-42871663-2026-10-15-72edcd9bc290`](#source-pubmed-observation-pmid-42871663-2026-10-15-72edcd9bc290))

#### Paragraph 1

PubMed lists PMID 42871663 in JCEM case reports as Case Reports, Journal Article, with publication-date metadata of 2026-10-13 (day precision). PeptideScanner associated the retained record with the identity slug palopegteriparatide. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings. ([`pubmed-observation-pmid-42871663-2026-10-15-72edcd9bc290`](#source-pubmed-observation-pmid-42871663-2026-10-15-72edcd9bc290))

#### Paragraph 2

This page reproduces bounded bibliographic metadata attributed to PubMed. Its title and publication details are source metadata, not PeptideScanner's endorsement or an assertion of safety, efficacy, or scientific truth. ([`pubmed-observation-pmid-42871663-2026-10-15-72edcd9bc290`](#source-pubmed-observation-pmid-42871663-2026-10-15-72edcd9bc290))

### Sources

<a id="source-pubmed-observation-pmid-42871663-2026-10-15-72edcd9bc290"></a>
- **Discontinuation of palopegteriparatide in chronic hypoparathyroidism without rebound hypocalcemia. · retained source version 1:2026-10-15:current:72edcd9bc2903abde6e389498761c605c56630794a4534fe3cff9cce30bb3d85** — PubMed; class A. [Open source](https://pubmed.ncbi.nlm.nih.gov/42871663/) (`pubmed-observation-pmid-42871663-2026-10-15-72edcd9bc290`)

### Correction lineage

No correction is recorded for this version.

### Reporting boundaries and unknowns

PeptideScanner reproduces bounded bibliographic metadata attributed to PubMed. It does not summarize or endorse the article's findings.

- Sources outside the selected public PeptideScanner bundle may exist and are not represented by this object.
- This object does not determine whether cited records agree, corroborate one another, or establish scientific truth.
- This object does not determine safety, efficacy, causality, or suitability for any person.

Methodology: https://peptidescanner.com/methodology/
Medical disclaimer: https://peptidescanner.com/medical-disclaimer/

### Suggested citation

PeptideScanner. "Discontinuation of palopegteriparatide in chronic hypoparathyroidism without rebound hypocalcemia." Version 1, published 2026-11-15. https://peptidescanner.com/evidence/v1/peptides/palopegteriparatide.json#pubmed-pmid-42871663-palopegteriparatide-v1 SHA-256: 669081e916a66e8c4aa5cece983ad88232aa9e9c2bb2eac82752ff96bda328ef.

---

<a id="pubmed-pmid-42924498-palopegteriparatide-v1"></a>

## Palopegteriparatide: Parathyroid Hormone Analog for the Treatment of Chronic Hypoparathyroidism in Adults.

> PubMed lists PMID 42924498 in The Annals of pharmacotherapy as Journal Article, Review, with publication-date metadata of 2026-10-23 (day precision). PeptideScanner associated the retained record with the identity slug palopegteriparatide. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.

- Evidence object: `story:pubmed-pmid-42924498-palopegteriparatide:v1`
- Evidence domain: Literature metadata
- Date in source: 2026-10-24
- Source checked: 2026-11-15
- Published by PeptideScanner: 2026-11-15
- Story landing page: https://peptidescanner.com/stories/pubmed-pmid-42924498-palopegteriparatide/
- JSON record: https://peptidescanner.com/evidence/v1/peptides/palopegteriparatide.json#pubmed-pmid-42924498-palopegteriparatide-v1
- Content SHA-256: `990d459ef7520632348f77f427c08da07197f17491cacc900dfde52d55f29da6`

### Claims and source pins

#### Headline

Palopegteriparatide: Parathyroid Hormone Analog for the Treatment of Chronic Hypoparathyroidism in Adults. ([`pubmed-observation-pmid-42924498-2026-10-24-0a8c8d3a1a73`](#source-pubmed-observation-pmid-42924498-2026-10-24-0a8c8d3a1a73))

#### Summary

PubMed lists PMID 42924498 in The Annals of pharmacotherapy as Journal Article, Review, with publication-date metadata of 2026-10-23 (day precision). PeptideScanner associated the retained record with the identity slug palopegteriparatide. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings. ([`pubmed-observation-pmid-42924498-2026-10-24-0a8c8d3a1a73`](#source-pubmed-observation-pmid-42924498-2026-10-24-0a8c8d3a1a73))

#### Paragraph 1

PubMed lists PMID 42924498 in The Annals of pharmacotherapy as Journal Article, Review, with publication-date metadata of 2026-10-23 (day precision). PeptideScanner associated the retained record with the identity slug palopegteriparatide. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings. ([`pubmed-observation-pmid-42924498-2026-10-24-0a8c8d3a1a73`](#source-pubmed-observation-pmid-42924498-2026-10-24-0a8c8d3a1a73))

#### Paragraph 2

This page reproduces bounded bibliographic metadata attributed to PubMed. Its title and publication details are source metadata, not PeptideScanner's endorsement or an assertion of safety, efficacy, or scientific truth. ([`pubmed-observation-pmid-42924498-2026-10-24-0a8c8d3a1a73`](#source-pubmed-observation-pmid-42924498-2026-10-24-0a8c8d3a1a73))

### Sources

<a id="source-pubmed-observation-pmid-42924498-2026-10-24-0a8c8d3a1a73"></a>
- **Palopegteriparatide: Parathyroid Hormone Analog for the Treatment of Chronic Hypoparathyroidism in Adults. · retained source version 1:2026-10-24:current:0a8c8d3a1a7372c3808ddc492482d6435ec8d3996a580ae1f1e850e5e01d5348** — PubMed; class A. [Open source](https://pubmed.ncbi.nlm.nih.gov/42924498/) (`pubmed-observation-pmid-42924498-2026-10-24-0a8c8d3a1a73`)

### Correction lineage

No correction is recorded for this version.

### Reporting boundaries and unknowns

PeptideScanner reproduces bounded bibliographic metadata attributed to PubMed. It does not summarize or endorse the article's findings.

- Sources outside the selected public PeptideScanner bundle may exist and are not represented by this object.
- This object does not determine whether cited records agree, corroborate one another, or establish scientific truth.
- This object does not determine safety, efficacy, causality, or suitability for any person.

Methodology: https://peptidescanner.com/methodology/
Medical disclaimer: https://peptidescanner.com/medical-disclaimer/

### Suggested citation

PeptideScanner. "Palopegteriparatide: Parathyroid Hormone Analog for the Treatment of Chronic Hypoparathyroidism in Adults." Version 1, published 2026-11-15. https://peptidescanner.com/evidence/v1/peptides/palopegteriparatide.json#pubmed-pmid-42924498-palopegteriparatide-v1 SHA-256: 990d459ef7520632348f77f427c08da07197f17491cacc900dfde52d55f29da6.

